These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 10747523)

  • 1. The UK strategy for monitoring universal leucodepletion.
    Beckman N; Seghatchian J
    Transfus Sci; 1999 Oct; 21(2):147-51. PubMed ID: 10747523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring universal leucodepletion performance: the current issues within components production and testing.
    Beckman N; Seghatchian J
    Transfus Apher Sci; 2001 Jun; 24(3):233-6. PubMed ID: 11791692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leucodepletion monitoring by flow cytometry (Becton-Dickinson): from universal to statistical process monitoring.
    Barclay R; McColl K; Walker B
    Transfus Sci; 2000; 22(1-2):63-4. PubMed ID: 10771385
    [No Abstract]   [Full Text] [Related]  

  • 4. Factors influencing the outcome of leucodepletion system.
    Seghatchian J; Krailadsiri P
    Transfus Sci; 2000; 22(1-2):135-7. PubMed ID: 10771402
    [No Abstract]   [Full Text] [Related]  

  • 5. National evaluation of IMAGN 2000 for quality monitoring of leucodepleted red cell and platelet concentrates: comparison with flow and Nageotte.
    Seghatchian J; Krailadsiri P; Chandegra B; Beard M; Beckman N; Bissett L; Morris B; Booker W
    Transfus Sci; 2000; 22(1-2):77-9. PubMed ID: 10771390
    [No Abstract]   [Full Text] [Related]  

  • 6. Evaluating leucodepletion systems suitable for routine use.
    Rowe G
    Transfus Sci; 2000; 22(1-2):61-2. PubMed ID: 10771384
    [No Abstract]   [Full Text] [Related]  

  • 7. Leucofiltration of sickle cell trait blood "the blocker": NBS London & S.E. experience.
    Beard MJ; Seghatchian J; Cardigan R; Bennett J; Smith KM; Williamson L
    Transfus Sci; 2000; 22(1-2):71-3. PubMed ID: 10771388
    [No Abstract]   [Full Text] [Related]  

  • 8. UK strategy for process qualification/validation: from concept to practical implementation.
    Beckman N; Seghatchian J
    Transfus Sci; 2000 Jun; 22(3):203-6. PubMed ID: 10831923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic RBC leucodepletion in France: where are we after six months?
    Masse M
    Transfus Sci; 2000; 22(1-2):57-9. PubMed ID: 10771383
    [No Abstract]   [Full Text] [Related]  

  • 10. nvCJD and leucodepletion: an overview.
    Seghatchian J
    Transfus Sci; 2000; 22(1-2):47-8. PubMed ID: 10771379
    [No Abstract]   [Full Text] [Related]  

  • 11. Selective or universal leucodepletion: the Italian experience.
    Accorsi P; Iacone A
    Transfus Sci; 2000; 22(1-2):65-7. PubMed ID: 10771386
    [No Abstract]   [Full Text] [Related]  

  • 12. Validation of different enrichment strategies for analysis of leucocyte sub-populations: development and application of a new approach, based on leucofiltration.
    Seghatchian J; Krailadsiri P
    Transfus Apher Sci; 2002 Feb; 26(1):61-72. PubMed ID: 11931379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies on the characterisation of the cause of leucoreduction failures, with particular reference to extra gatal events.
    Seghatchian J; Krailadsiri P; Beard M; Bukasa A; Bashir S
    Transfus Apher Sci; 2002 Feb; 26(1):47-60. PubMed ID: 11931378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NBS approaches to the approval of suppliers of leucodepletion systems.
    Smith KJ
    Transfus Sci; 1998 Dec; 19(4):371-2. PubMed ID: 10351159
    [No Abstract]   [Full Text] [Related]  

  • 15. International views on universal leucodepletion: the perspective in NBS, England.
    Wallington T
    Transfus Sci; 1998 Dec; 19(4):347-8. PubMed ID: 10351150
    [No Abstract]   [Full Text] [Related]  

  • 16. Leucodepletion and regulatory aspects in Germany.
    Heiden M; Keller-Stanislawski B
    Transfus Sci; 2000; 22(1-2):69-70. PubMed ID: 10771387
    [No Abstract]   [Full Text] [Related]  

  • 17. [The quality concept. The French Graft Establishment].
    Giraud Ch; Korach JM; Andreu G; Lacaze C; Vaicle M; Schooneman F; Guillevin L
    Transfus Clin Biol; 2002 Jul; 9(3):229-32. PubMed ID: 12357705
    [No Abstract]   [Full Text] [Related]  

  • 18. Quality assurance and quality control in component preparation.
    Pietersz RN
    Vox Sang; 1994; 67 Suppl 3():197-9. PubMed ID: 7975492
    [No Abstract]   [Full Text] [Related]  

  • 19. Challenges in QA of leucodepleted blood component and current standard(s). Challenges in quality assurance of leukoreduced components.
    Dumont LJ
    Transfus Sci; 1998 Dec; 19(4):377-80. PubMed ID: 10351162
    [No Abstract]   [Full Text] [Related]  

  • 20. A simple flow-cytometric method for absolute counting of residual white blood cells in leukocyte-reduced packed red cells.
    Gómez-Arbonés X; Pinacho A; Ortiz P; Maciá J; Gallart M; Araguás C; Sánchez JM; Teixidó M
    Vox Sang; 1999; 76(1):64-5. PubMed ID: 9933857
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.